

Half-Year Summary of Activities – 31 December 2016

Genetic Signatures (ASX: GSS) is pleased to report on its activities for the half-year period ended 31 December 2016.

Highlights

Sales Growth of 18% for the Half-Year

- \$1m revenue generated during the period.

Global Market Expansion

- Genetic Signatures selected to present at the 27th European Congress of Clinical Microbiology and Infectious Diseases in April, where it will highlight the improved detection of Flaviviruses with proprietary *3Base*[™] technology.
- Exhibited at the 24th International Molecular Med Tri-Con in San Francisco during February. Other conferences exhibited at include the 65th American Society of Tropical Medicine and Hygiene Meeting in November and the 16th Asia Pacific Congress of Clinical Microbiology and Infection in December.

Product Range Expansion

- Validation completed for the *EasyScreen*[™] Sexually Transmitted Infection (STI) Detection Kit, which includes routine detection of dangerous Chlamydia serovars (LGV).
- The STI Detection Kit will be released for Research Use Only in the March 2017 Quarter, with further work continuing on Australian and European regulatory approvals for full registration.
- Research and development on new kits and assays continues including kits for atypical respiratory infections, antibiotic resistance, Flavivirus (including Zika) and meningitis.

Corporate

- \$15m Capital raising completed, strengthening balance sheet and laying foundation for strong future growth.
- \$1.4m Research and Development Tax Concession received from the Australian Federal Government.
- \$16m Cash and equivalents in hand as at 31 December 2016.

Upcoming Activities

- *EasyScreen*[™] (STI) Detection Kit being prepared for commercial release in Australia and Europe.
 - Genetic Signatures has commenced the FDA regulatory approval process.
 - Focus remains on sales growth, product range extension and market share expansion.
-

Commentary

The loss for the consolidated entity after providing for income tax amounted to \$1,339,595 (31 December 2015: \$1,612,844).

Genetic Signatures recorded revenue growth for the period ended 31 December 2016, with total sales revenue growth of 18% on the previous corresponding half.

During the half, the Company received the proceeds of the \$15m capital raising, strengthening its balance sheet and laying a strong foundation for future growth. With an estimated US\$2.1bn addressable global market in 2017, these funds are being directed to accelerate the Company's global expansion strategy, which will prioritise the United States and Europe.

In addition to growing our international client base, the Company will focus on furthering molecular diagnostic approvals for existing and new products in key global markets that will drive revenue further in other product categories along with shareholder value.

The Company is also focusing on accelerated validation and development of its current and new product range, including advancing research and development of five new diagnostic products.

Genetic Signatures' outlook remains focused on achieving strong revenue growth, progressing significant offshore opportunities and driving shareholder value. Collectively this supports the Company's long-term goal of continuing to target health conditions where faster and more accurate diagnosis plays a pivotal role in improving community health both in Australia and across the globe.

The Company received a Research and Development Tax Concession (grant income) of \$1,429,887 from the Australian Federal Government. Total cash receipts for the period including this grant and the capital raising were \$17,456,556.

At 31 December 2016, the company held \$16,008,374 in cash and equivalents.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 (0)412 036 231

About Genetic Signatures: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, *3Base*[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures' proprietary MDx *3Base*[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Genetic Signatures Limited
ABN:	30 095 913 205
Reporting period:	For the half-year ended 31 December 2016
Previous period:	For the half-year ended 31 December 2015

2. Results for announcement to the market

				\$
Revenues from ordinary activities	up	17.74%	to	1,003,175
(Loss) from ordinary activities after tax attributable to the owners of Genetic Signatures Limited	down	16.94%	to	(1,339,595)
(Loss) for the half-year attributable to the owners of Genetic Signatures Limited	down	16.94%	to	(1,339,595)

Dividends

No dividend has been declared for the half-year ended 31 December 2016.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$1,339,595 (31 December 2015: \$1,612,844).

Genetic Signatures recorded revenue growth for the period ended 31 December 2016, with total sales revenue growth of 17.74% on the previous corresponding half.

During the half, the Company received the proceeds of the \$15M capital raising, strengthening its balance sheet and laying a strong foundation for future growth. With an estimated US\$2.1B addressable global market in 2017, these funds are being directed to accelerate the Company's global expansion strategy, which will prioritise the United States and Europe.

In addition to growing our international client base, the Company will focus on furthering molecular diagnostic approvals for existing and new products in key global markets that will drive revenue further in other product categories along with shareholder value.

The Company is also focusing on accelerated validation and development of its current and new product range, including advancing research and development of five new diagnostic products.

Genetic Signatures' outlook remains focused on achieving strong revenue growth, progressing significant offshore opportunities and driving shareholder value. Collectively this supports the Company's long-term goal of continuing to target health conditions where faster and more accurate diagnosis plays a pivotal role in improving community health both in Australia and across the globe.

The Company received a Research and Development Tax Concession (grant income) of \$1,429,887 from the Australian Federal Government. Total cash receipts for the period including this grant and the capital raising were \$17,456,556.

At 31 December 2016, the company held \$16,008,374 in cash.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	16.89	7.81

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

Details of review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Half Year Report.

8. Attachments

Details of attachments (if any):

The Half Year Report of Genetic Signatures Limited for the half-year ended 31 December 2016 is attached.

9. Signed



Signed _____

Date: 27 February 2017

John Melki
Director
Sydney

Genetic Signatures Limited

ABN 30 095 913 205

Half Year Report - 31 December 2016

Genetic Signatures Limited
Directors' Report
31 December 2016

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Genetic Signatures Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2016.

Directors

The following persons were directors of Genetic Signatures Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Nickolaos Samaras
John Melki
Phillip Isaacs
Michael Aicher
Anthony Radford AO

Principal activities

During the financial half-year the principal continuing activities of the consolidated entity consisted of the research and commercialisation of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$1,339,595 (31 December 2015: \$1,612,844).

Genetic Signatures recorded revenue growth for the period ended 31 December 2016, with total sales revenue growth of 17.74% on the previous corresponding half.

During the half, the Company received the proceeds of the \$15M capital raising, strengthening its balance sheet and laying a strong foundation for future growth. With an estimated US\$2.1B addressable global market in 2017, these funds are being directed to accelerate the Company's global expansion strategy, which will prioritise the United States and Europe.

In addition to growing our international client base, the Company will focus on furthering molecular diagnostic approvals for existing and new products in key global markets that will drive revenue further in other product categories along with shareholder value.

The Company is also focusing on accelerated validation and development of its current and new product range, including advancing research and development of five new diagnostic products.

Genetic Signatures' outlook remains focused on achieving strong revenue growth, progressing significant offshore opportunities and driving shareholder value. Collectively this supports the Company's long-term goal of continuing to target health conditions where faster and more accurate diagnosis plays a pivotal role in improving community health both in Australia and across the globe.

The Company received a Research and Development Tax Concession (grant income) of \$1,429,887 from the Australian Federal Government. Total cash receipts for the period including this grant and the capital raising were \$17,456,556. At 31 December 2016, the company held \$16,008,374 in cash.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year, other than the completion of the oversubscribed capital raising which raised \$15,027,973 (before capital raising costs).

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 3.

Genetic Signatures Limited
Directors' report
31 December 2016

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



John Melki
Director

27 February 2017
Sydney

DECLARATION OF INDEPENDENCE BY MARTIN COYLE TO THE DIRECTORS OF GENETIC SIGNATURES LIMITED

As lead auditor for the review of Genetic Signatures Limited for the half-year ended 31 December 2016, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Genetic Signatures Limited and the entities it controlled during the period.



Martin Coyle
Partner

BDO East Coast Partnership

Sydney, 27 February 2017

Genetic Signatures Limited

Contents

31 December 2016

Contents

Consolidated statement of profit or loss and other comprehensive income	5
Consolidated statement of financial position	6
Consolidated statement of changes in equity	7
Consolidated statement of cash flows	8
Notes to the consolidated financial statements	9
Directors' declaration	12
Independent auditor's review report to the members of Genetic Signatures Limited	13

Genetic Signatures Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office

Level 12
680 George Street
Sydney NSW 2000

Principal place of business

Level 9
405 Liverpool Street
Darlinghurst NSW 2010

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27 February 2017.

Genetic Signatures Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2016

		Consolidated	
	Note	31 Dec 2016	31 Dec 2015
		\$	\$
Revenue and other income	2	1,929,609	1,504,705
Expenses			
Raw materials and consumables used		(218,664)	(275,350)
Employee benefits expense		(1,393,592)	(1,641,645)
Consultancy fees		(278,097)	(168,357)
Depreciation and amortisation expense		(229,235)	(187,260)
Rental expenses relating to operating leases		(104,872)	(85,386)
Scientific consumables		(503,919)	(274,326)
Travel and accommodation		(76,843)	(84,442)
Other expenses		(463,840)	(399,657)
Finance costs	3	(142)	(1,126)
Loss before income tax expense		(1,339,595)	(1,612,844)
Income tax expense		-	-
Loss after income tax expense for the half-year		(1,339,595)	(1,612,844)
Other comprehensive loss for the half-year, net of tax		-	-
Total comprehensive income for the half-year		<u>(1,339,595)</u>	<u>(1,612,844)</u>
Loss for the half-year is attributable to:			
Owners of Genetic Signatures Limited		<u>(1,339,595)</u>	<u>(1,612,844)</u>
		<u>(1,339,595)</u>	<u>(1,612,844)</u>
Total comprehensive loss for the half-year is attributable to:			
Owners of Genetic Signatures Limited		<u>(1,339,595)</u>	<u>(1,612,844)</u>
		<u>(1,339,595)</u>	<u>(1,612,844)</u>
		Cents	Cents
Basic earnings per share	9	(1.52)	(2.21)
Diluted earnings per share		(1.52)	(2.21)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Genetic Signatures Limited
Consolidated statement of financial position
As at 31 December 2016

	Consolidated	
	31 Dec 2016	30 Jun 2016
	\$	\$
Assets		
Current assets		
Cash and cash equivalents	16,008,374	2,564,254
Trade and other receivables	789,195	485,216
Inventories	673,798	754,336
Current tax asset	844,900	1,429,887
Total current assets	<u>18,316,267</u>	<u>5,233,693</u>
Non-current assets		
Property, plant and equipment	728,463	729,471
Total non-current assets	<u>728,463</u>	<u>729,471</u>
Total assets	<u>19,044,730</u>	<u>5,963,164</u>
Liabilities		
Current liabilities		
Trade and other payables	1,073,126	931,286
Provisions	333,355	344,813
Total current liabilities	<u>1,406,481</u>	<u>1,276,099</u>
Non-current liabilities		
Provisions	10,971	7,360
Total non-current liabilities	<u>10,971</u>	<u>7,360</u>
Total liabilities	<u>1,417,452</u>	<u>1,283,459</u>
Net assets	<u>17,627,278</u>	<u>4,679,705</u>
Equity		
Issued capital	46,777,792	32,547,402
Reserves	685,819	738,001
Accumulated losses	(29,836,333)	(28,605,698)
Equity attributable to the owners of Genetic Signatures Limited	<u>17,627,278</u>	<u>4,679,705</u>
Total equity	<u>17,627,278</u>	<u>4,679,705</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Genetic Signatures Limited
Consolidated statement of changes in equity
For the half-year ended 31 December 2016

Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2015	32,501,357	151,046	(25,595,434)	7,056,969
Loss after income tax expense for the half-year	-	-	(1,612,844)	(1,612,844)
Total comprehensive loss for the half-year	-	-	(1,612,844)	(1,612,844)
<i>Transactions with owners in their capacity as owners:</i>				
Contributions of Equity, net of transaction costs (note 4)	(15,234)	-	-	(15,234)
Share Based Payment	-	269,932	-	269,932
Balance at 31 December 2015	<u>32,486,123</u>	<u>420,978</u>	<u>(27,208,278)</u>	<u>5,698,823</u>
Consolidated	Issued capital \$	Reserves \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2016	32,547,402	738,001	(28,605,698)	4,679,705
Loss after income tax expense for the half-year	-	-	(1,339,595)	(1,339,595)
Total comprehensive loss for the half-year	-	-	(1,339,595)	(1,339,595)
Transactions with owners in their capacity as owners:	-	(3,118)	-	(3,118)
Contributions of Equity, net of transaction costs (note 4)	14,230,390	-	-	14,230,390
Forfeiture of share-based payments	-	(108,960)	108,960	-
Share based payment	-	59,896	-	59,896
Balance at 31 December 2016	<u>46,777,792</u>	<u>685,819</u>	<u>(29,836,333)</u>	<u>17,627,278</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Genetic Signatures Limited
Consolidated statement of cash flows
For the half-year ended 31 December 2016

	Consolidated	
Note	31 Dec 2016	31 Dec 2015
	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	947,135	836,687
Payments to suppliers and employees (inclusive of GST)	(2,983,367)	(2,770,403)
Interest received	51,561	49,770
R&D grant	1,429,887	967,879
Interest and other finance costs paid	(142)	(1,126)
Net cash used in operating activities	(554,926)	(917,193)
Cash flows from investing activities		
Payments for property, plant and equipment	(228,227)	(214,078)
Net cash used in investing activities	(228,227)	(214,078)
Cash flows from financing activities		
Proceeds from issue of shares	15,027,973	-
Share issue costs	(797,582)	(15,234)
Net cash provided by/(used in) financing activities	14,230,391	(15,234)
Net increase/(decrease) in cash and cash equivalents	13,447,238	(1,146,505)
Cash and cash equivalents at the beginning of the financial half-year	2,564,254	5,461,686
Effects of exchange rate changes on cash and cash equivalents	(3,118)	-
Cash and cash equivalents at the end of the financial half-year	16,008,374	4,315,181

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Genetic Signatures Limited
Notes to the consolidated financial statements
31 December 2016

Note 1. Significant accounting policies

Basis of preparation of half-year report

These general purpose financial statements for the half-year reporting period ended 31 December 2016 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2016 and any public announcements made by the company during the half year reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding half year reporting period.

New, revised or amending Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

None of the new standards and amendments to standards that are mandatory for the first time for the financial year beginning 1 July 2016 affected any amounts recognised in the current period or any prior period financial statements and are not likely to affect future period financial statements.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Fair value

Due to their short term nature, the Directors considered the carrying amounts of cash, current receivables and current payables to approximate to their fair value.

Note 2. Revenue

	Consolidated	
	31 Dec 2016	31 Dec 2015
	\$	\$
<i>Sales revenue</i>		
Sale of goods	968,814	890,224
Interest	87,750	55,425
	<u>1,056,564</u>	<u>945,649</u>
<i>Other income</i>		
Government Grant (R & D tax concession)	844,900	558,862
Other income	28,145	194
	<u>873,045</u>	<u>559,056</u>
Revenue and other income	<u><u>1,929,609</u></u>	<u><u>1,504,705</u></u>

Genetic Signatures Limited
Notes to the consolidated financial statements
31 December 2016

Note 3. Expenses

	Consolidated	
	31 Dec 2016	31 Dec 2015
	\$	\$
Loss before income tax includes the following specific expenses:		
<i>Cost of sales</i>		
Cost of sales	218,664	275,350
<i>Finance costs</i>		
Interest and finance charges paid/payable	142	1,126
<i>Rental expense relating to operating lease</i>		
Minimum lease payments	104,872	85,386
<i>Superannuation expense</i>		
Defined contribution superannuation expense	100,101	96,403
<i>Net foreign exchange loss</i>		
Net foreign exchange loss	-	6,905
<i>Included in other expenses are</i>		
IPO costs expensed	-	14,525

Note 4. Equity – Share issue costs

Share issue costs paid during the half-year were as follows:

	Consolidated	
	31 Dec 2016	31 Dec 2015
	\$	\$
Proceeds from the issue of shares	15,027,973	-
Share issue costs	(797,582)	(15,234)
Net proceeds from the issue of shares	<u>14,230,391</u>	<u>(15,234)</u>

Note 5. Contingent liabilities

The consolidated entity does not have any material contingent liabilities at period-end.

Genetic Signatures Limited
Notes to the consolidated financial statements
31 December 2016

Note 6. Events after the reporting period

No matter or circumstance has arisen since 31 December 2016 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 7. Financial Reporting Segments

The consolidated entity operates under one business segment which is the research and commercialisation of the identification of genetic signatures that identify diseases and viruses. The activities were undertaken predominantly in Australia.

Note 8. Dividends

The consolidated entity has not declared or paid a dividend during the half-year.

Note 9. Earnings per share

	Consolidated	
	31 Dec 2016	31 Dec 2015
	\$	\$
Loss after income tax	(1,339,595)	(1,612,844)
Loss after income tax attributable to the owners of Genetic Signatures Limited	(1,339,595)	(1,612,844)
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	88,016,964	72,881,613
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares ¹	-	-
Weighted average number of ordinary shares used in calculating diluted earnings per share	88,016,964	72,881,613
	Cents	Cents
Basic loss per share	(1.52)	(2.21)
Diluted loss per share	(1.52)	(2.21)

¹ Options were antidilutive in both the current and comparative period and thus not included in the dilutive loss per share calculation

Note 10. Capital commitments

Capital Commitments relate to an item of plant and equipment where funds have been committed but the assets not yet received amounting to \$115,200.

Genetic Signatures Limited
Directors' declaration
31 December 2016

In the directors' opinion:

- The attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- The attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the financial half-year ended on that date; and
- There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors



John Melki
Director

27 February 2017
Sydney

INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Genetic Signatures Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Genetic Signatures Limited, which comprises the consolidated statement of financial position as at 31 December 2016, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, notes comprising a statement of accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year's end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Genetic Signatures Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Genetic Signatures Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.



Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Genetic Signatures Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2016 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

BDO East Coast Partnership

A handwritten signature in dark ink, appearing to read 'Martin Coyle', is written over a faint, larger 'BDO' logo.

Martin Coyle
Partner

Sydney, 27 February 2017